Story perspectives

Eli Lilly Launches Zepbound KwikPen for Obesity Treatment

2/24/2026

Summary

Story summary

Eli Lilly launched the Zepbound KwikPen on February 23, 2026, a multi-dose injection device.
The KwikPen delivers four weekly doses in one device and costs $299 per month.
The Food and Drug Administration (FDA) approved the KwikPen, available through LillyDirect alongside single-dose vials.
Zepbound, containing tirzepatide, is approved for obesity and obstructive sleep apnea.
The launch followed strong demand, with Zepbound becoming the top weight-management medication in 2025.

History

Historical Context

In November 2023, the FDA approved tirzepatide, marketed as Zepbound, for obesity treatment, following its earlier approval for diabetes in May 2022. Eli Lilly reported over $1 billion in sales within the first year, reflecting the urgent need for effective obesity solutions as U.S. obesity rates reached 42.4% in 2020, highlighting a growing focus on chronic disease management.

1 of 2

Story summary

Eli Lilly launched the Zepbound KwikPen on February 23, 2026, a multi-dose injection device.
The KwikPen delivers four weekly doses in one device and costs $299 per month.
The Food and Drug Administration (FDA) approved the KwikPen, available through LillyDirect alongside single-dose vials.
Zepbound, containing tirzepatide, is approved for obesity and obstructive sleep apnea.
The launch followed strong demand, with Zepbound becoming the top weight-management medication in 2025.

1 / 2